Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Journey Medical CorporationNASDAQ: DERM
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $1.15M rose 5.8% year over year, behind the +17.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 5.6% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.
Context
- Depreciation & amortization amounted to 7.6% of revenue in FY2025, up 1.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +5.8% toward the trailing-twelve-month pace of +17.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 4.72M USD
- Year-over-year change
- +38.0%
- 4-year CAGR
- +16.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.72M | +38.0% |
| FY2024 | 2024-12-31 | 3.42M | -11.2% |
| FY2023 | 2023-12-31 | 3.86M | -11.7% |
| FY2022 | 2022-12-31 | 4.37M | +70.5% |
| FY2021 | 2021-12-31 | 2.56M | — |
Depreciation & Amortization vs competitors
How DERM compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +17.1% is the 5th highest of 10, against a peer median of +13.1%.
- Depreciation & amortization amounts to 6.8% of revenue for DERM, versus a peer median of 8.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$19.77M CAD | +37.9% | — | 7.2% | |
| LTM Mar 2026 | $9.86M USD | -9.2% | -91.3% | 8.7% | |
| LTM Mar 2026 | €5.43M EUR | +88.5% | +32.4% | 33.3% | |
| LTM Mar 2026 | $4.41M USD | +17.1% | +2.7% | 6.8% | |
| FY2025 | €3.22M EUR | -38.0% | +23.8% | 71.9% | |
| LTM Mar 2026 | $2.42M USD | +13.1% | +32.0% | 136.2% | |
| LTM Mar 2026 | $1.88M USD | +27.6% | +10.4% | 13.0% | |
| LTM Mar 2026 | $672K USD | +1192.3% | +30.5% | 7.0% | |
| LTM Mar 2026 | $334K USD | +5.4% | +13.8% | 1.0% | |
| LTM Mar 2026 | $103K USD | -59.6% | -11.6% | 0.2% | |
| Peer median (excluding DERM) | — | +13.1% | +18.8% | 8.7% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.42M | 4.72M |
| Deferred Income Tax | 1.57M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.47M | 4.43M | 2.61M | 6.1M | 6.29M |
| Change in Working Capital | 14.71M | 6.19M | (1.66M) | (3.77M) | (11.9M) |
| Accounts Receivables | 768K | (5.38M) | 12.55M | 4.48M | (19.34M) |
| Inventory | (8.46M) | 1.74M | 3.95M | (4.23M) | 4.81M |
| Accounts Payables | 21.71M | 14.34M | (18.42M) | (2.1M) | (7.27M) |
| Other Working Capital | 686K | (4.52M) | 262K | (1.92M) | 9.91M |
| Other Non-Cash Items | 20.51M | 1.12M | 4.29M | (211K) | (123K) |
| Operating Cash Flow | (2.18M) | (13.53M) | 5.24M | (9.13M) | (12.44M) |
| Capital Expenditures | (10M) | (20M) | (5M) | (15M) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (10M) | (20M) | (5M) | (15M) | 0 |
| Debt Repayment | 5.05M | 16.9M | (8.95M) | 8.7M | 15.73M |
| Common Stock Issued | 32.54M | 142K | 4.49M | 8.29M | 16.93M |
| Common Stock Repurchased | 0 | (371K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 16.97M | (214K) | (350K) | (50K) | (16.43M) |
| Financing Cash Flow | 53.02M | 16.46M | (4.8M) | 16.99M | 16.23M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 40.84M | (17.08M) | (4.56M) | (7.13M) | 3.79M |
| Free Cash Flow | (12.18M) | (33.53M) | 240K | (9.13M) | (12.44M) |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.